(5-甲基-2-硝基苯基)肼 | 56637-42-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (5-甲基-2-硝基苯基)肼
• 英文名称: 5-methyl-2-nitrophenylhydrazine
• 英文别名: 1-(5-Methyl-2-nitrophenyl)hydrazine；(5-methyl-2-nitrophenyl)hydrazine
• CAS: 56637-42-4
• 化学式: C₇H₉N₃O₂
• 分子量: 167.167
• InChiKey: ZFSWIJVMQFUDEG-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C
• 沸点：
  325.1±30.0 °C(Predicted)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  83.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-甲基-2-硝基苯基)肼 在 copper(II) sulfate 、 溶剂黄146 作用下， 生成 4-硝基甲苯
  参考文献：
  名称：

  Mangini; Colonna, Gazzetta Chimica Italiana, 1938, vol. 68, p. 708,713

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氟-4-硝基甲苯 在 sodium carbonate 、 一水合肼 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以75%的产率得到(5-甲基-2-硝基苯基)肼
  参考文献：
  名称：

  Albini, Angelo; Bettinetti, Gianfranco; Minoli, Giovanna, Heterocycles, 1995, vol. 40, # 2, p. 597 - 606

  摘要：

  DOI：

文献信息

• BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：AgeneBio, Inc.

  公开号：US20180170941A1

  公开（公告）日：2018-06-21

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患有与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、瑞特综合症、强迫行为和物质成瘾。它还涉及在治疗与之相关的脑癌（包括脑肿瘤，例如髓母细胞瘤）和认知障碍的情况下，如本文所述使用α5含有的GABAA受体激动剂（例如，α5含有的GABAA受体正向变构调节剂）。
• New Synthetic Route to Cinnoline Derivatives and Their Microbiological Activity
  作者：H. Lettreuch、M. Khodja、H. Boutoumi

  DOI：10.1134/s1070428020120222

  日期：2020.12

  New cinnoline derivatives have been synthesized by reductive cyclization of hydrazones obtained by condensation of various 2-nitrophenylhydrazine derivatives with methyl pyruvate and dimethyl acetylenedicarboxylate. Microbiological tests of these new derivatives were carried out against four bacterial strains, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Bacillus subtilis

  已通过将各种 2-硝基苯肼衍生物与丙酮酸甲酯和乙炔二甲酸二甲酯缩合得到的腙还原环化合成了新的吖啶衍生物。对这些新衍生物进行了针对四种细菌菌株（大肠杆菌、金黄色葡萄球菌、表皮葡萄球菌和枯草芽孢杆菌）以及两种真菌菌株（酿酒酵母和白色念珠菌）的微生物测试。合成的化合物表现出良好至中等的活性。
• 1,2,4-Triazolo[1,5-<i>a</i>]quinoxaline as a Versatile Tool for the Design of Selective Human A₃ Adenosine Receptor Antagonists:  Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives
  作者：Daniela Catarzi、Vittoria Colotta、Flavia Varano、Ombretta Lenzi、Guido Filacchioni、Letizia Trincavelli、Claudia Martini、Christian Montopoli、Stefano Moro

  DOI：10.1021/jm0504149

  日期：2005.12.1

  A number of 4-oxo-substituted 1,2,4-triazolo[1,5-alquinoxaline derivatives bearing at position-2 the claimed (hetero)aryl moiety (compounds 1-15) but also a carboxylate group (16-28, 3236) or a hydrogen atom (29-31) were designed as human A(3) (hA(3)) adenosine receptor (AR) antagonists. This study produced some interesting compounds and among them the 2-(4methoxyphenyl)-1,2,4-triazolo[1,5-alquinoxalin-4-one (8), which can be considered one of the most potent and selective hA(3) adenosine receptor antagonists reported till now. Moreover, as a new finding, replacement of the classical 2-(hetero)aryl moiety with a 2-carboxylate function (compounds 16-28 and 32-36) maintained good hA(3) AR binding activity but, most importantly and interestingly, produced a large increase in bA(3) versus hA(1) selectivity. A receptor-based SAR analysis provided new interesting insights about the steric and electrostatic requirements that are important for the anchoring of these derivatives at the hA(3) receptor recognition site, thus highlighting the versatility of the triazoloquinoxaline scaffold for obtaining potent and selective hA(3) AR antagonists.
• Catarzi; Cecchi; Colotta, Il Farmaco, 1993, vol. 48, # 8, p. 1065 - 1078
  作者：Catarzi、Cecchi、Colotta、Melani、Filacchioni、Martini、Giusti、Lucacchini

  DOI：——

  日期：——
• Mangini, Ricerca Scientifica, 1937, vol. 8 II, p. 248
  作者：Mangini

  DOI：——

  日期：——